Booking Health, a leading platform for international medical travel, announced today the release of its 2026 rankings of ...

Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?

The centre houses an <a href=" Harmony Pro linear accelerator, one of the most advanced radiotherapy systems in the world ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...

Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Nancy Frandsen looks back on her career, from answering a paralegal advert to expanding RCCB’s ‘entrepreneurial’ IP practice ...